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Abstract 
Myocardial infarction (MI) is one of the leading causes of death associated with 
cardiovascular disease affecting approximately 735,000 Americans each year. The 
resulting damage caused by MI initiates a pathological progression towards congestive 
heart failure. Donor shortages rule out transplantation as a viable treatment option and 
coronary revascularization does not solve the issue of regenerating the infarct scar. Stem 
cell therapies, however, show great potential, but have been largely unsuccessful at 
regenerating diseased myocardium. This study aims to differentiate human adipose 
derived stem cells (hADSCs) by methods of co-culture and chemical induction to 
produce functional cardiomyocytes, as well as by mechanical and electrical stimulation in 
a bioreactor. Ultimately, pre-differentiated cardiomyocytes could be implanted into 
diseased patients in order to provide a functional myocardial patch. Chemical induction 
of hADSCs by a DNA methylation inhibitor, 5-Azacytidine, produced differentiated 
cardiomyocytes that expressed cardiac-specific desmin, a type III muscle intermediate 
filament that regulates sarcomere architecture. ADSCs were also co-cultured with human 
embryonic stem cell derived cardiomyocytes on well plates in order to induce the 
differentiation of hADSCs towards cardiomyocytes. Co-cultured cells expressed cardiac-
specific troponin T, cardiac myosin heavy chain, alpha-actinin, and desmin. Although the 
co-cultured cells did express myocyte markers, these cells did not express significantly 
more protein than the hESC cardiomyocytes cultured alone. These findings suggest that 
this method of differentiating hADSCs may not be a clinically viable option. Further, 
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decellularized porcine myocardium was used as a scaffold to seed hADSCs in a 
bioreactor and was introduced to both mechanical and electrical stimuli to simulate 
physiological conditions. After 3 weeks of culture, the myocardial patches were analyzed 
for cardiac-specific proteins and were confirmed to express all of the previously tested 
markers. The myocardial patches did not allow for good cell infiltration into the tissue so 
further seeding tests need to be conducted to optimize cell penetration. Future studies will 
integrate the co-culture method as well as the chemical treatment method with the 
bioreactor to optimize the differentiation of hADSCs towards cardiomyocytes. 
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Chapter 1: Review of Literature 
 2 
1.1 Heart Physiology 
Myocardial infarction (MI) is commonly known as a heart attack and is the 
leading cause of deaths in middle and upper income countries and is second in lower 
income countries only to lower respiratory diseases1. MIs are characterized by shortness 
of breath, chest pains, left arm pain, and fatigue among other symptoms and is due to a 
decrease in blood supply to the heart which reduces oxygen levels available to cardiac 
muscles.  
The cardiovascular or circulatory system is comprised of the heart, blood vessels, 
and blood which carry nutrients and oxygen throughout the body. Blood is made up of 
several cell types including erythrocytes, platelets, and leukocytes suspended in plasma 
of inorganic material: salts, water, hormones, and proteins. In considering myocardial 
infarction, erythrocytes are most important since they carry the oxygen necessary for 
cardiac muscle functionality and remove the resulting carbon dioxide. Its ability to carry 
large amounts of oxygen comes from the hemoglobin protein’s four iron molecules that 
can each bind to O2 allowing erythrocytes to carry more oxygen than plasma alone. In 
following the pathway of blood, it leaves the right ventricle and is pumped into the 
pulmonary circuit where the hemoglobin attracts oxygen in the lungs. The blood then 
returns to the left side of the heart and is pumped through the aortic valve into the aorta 
connected to arteries that flow to the rest of the body. These include the right and left 
coronary arteries which supply blood and oxygen to the myocardium or heart muscle. 
From the arteries, blood travels to arterioles then to capillaries where the oxygen is 
released into tissues. From capillaries, the deoxygenated blood travels to venules and 
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onward to veins and the vena cava which returns it to the heart. In particular, the coronary 
sinus is the vein which will return deoxygenated blood from the heart to the vena cava.  
The heart is composed of four chambers which pump the blood separated by 
valves to prevent backflow of blood. The walls of the heart include several layers: 
epicardium, myocardium, and endocardium. The endocardium is the inner lining of the 
heart wall made up of endothelial cells that prevent the blood from clotting. The 
myocardium refers to the myoblasts which are responsible for the contraction and 
relaxation that result in pumping the blood. The outer layer is the epicardium which 
secretes the pericardial fluid and can also be considered as part of the pericardium. The 
fluid is contained in the pericardial sac to protect the heart from shock or jerking motions. 
As in all muscle contractions, the heart’s pumping motion is controlled by electrical 
signals causing long fibrous proteins of the muscle called sarcomeres to slide along each 
other. In this case, the electrical signal is generated by the sinoatrial node. It travels down 
the atrial intra-nodal and intra-atrial pathways, slows at the atrioventricular node to allow 
for atrial contraction, and ends at the Purkinje fibers which cause ventricular contraction. 
When occlusion in the bloodstream occurs, the myocardium receives insufficient 
nutrients and oxygen to contract which results in inconsistent or weak beating and 
myocardial infarction. 
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Figure 1.1: Schematic of the three layers of the wall of the heart. Image taken from http://www2.highlands.edu/ 
When blood flows through the heart, the left and right ventricles are the chief 
contributors in creating enough force to direct the blood where it needs to go. The right 
ventricle pumps the blood into the pulmonary circuit in order to obtain oxygen from the 
lungs and the left ventricle sends blood into the systemic circuit to disperse the blood’s 
nutrients throughout the rest of the body.  Because the left ventricle has to create enough 
force to send the blood throughout the entire body, it must generate more force than the 
other parts of the heart are required to. 
 The myocardial cell is the basic unit comprising the heart muscle that beats 
synchronously with adjacent cells in order to produce the pumping action of the heart. 
Ultimately, blood is moved throughout the body into organs and peripheral tissues.  The 
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cells are approximately 25 µm in diameter and are 200 µm in length containing bundles 
of myofibrils each containing bundles of myofilaments. Microfilament structures consist 
of repeating segments of sarcomeres, the segment comprising of all structures between 
two Z lines, containing thin filaments and thick filaments. These microscopic filaments 
are made up of actin and myosin complexes respectively. Contraction of the cardiac 
myocyte occurs when an influx of Ca2+ ions binds to the Troponin-C (TNC) complex and 
induces the sliding of the actin filaments over the myosin filaments by a cross bridging 
action leading to shortening of sarcomeres as Z lines move closer together. The cardiac 
muscle is considered a syncytium, a multinucleated cell, although the muscle fibers are 
separated by their distinct sarcolemmas and each myofibril is separated by dense 
intercalated disks, the cardiac muscle as a whole functions as a syncytium. When a wave 
of electrical excitation moves through a cardiac cell, it passes through the gap junction 
found in the intercalated disk area between adjoining cells. Due to the high conductance 
of these structures, the gap junctions allow cells to communicate with each other to 
produce a synchronous contraction which ultimately leads to the beating of the heart 
muscle.  
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Figure 1.2 Microstructure of the cardiac myocyte fiber. Image taken from www.openstax.org. 
 
 A fibrillar collagen network surrounds groups of myocytes and connect them to 
each other as well as neighboring capillary networks. This network consists mainly of 
collagen types I and III, which ultimately maintain tissue architecture and provide the 
optimal stiffness for systolic conditions of the cardiac cycle. Additionally, fibroblasts are 
abundantly present in the heart muscle as they comprise of approximately two-thirds of 
the cells in the tissue. They function mainly to lay down collagen and repair the 
extracellular matrix in the event of damage to the tissue. Additionally, cardiac cells and 
fibroblasts form gap junctions between each other in addition to the gap junctions 
between adjacent myocytes. These connections suggest that fibroblasts may share a role 
in the electrical conduction system of the heart.  
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1.2 Pathology 
Coronary artery disease is defined as the formation of an atherosclerotic plaque in the 
coronary arteries that can lead to angina pectoris, myocardial infarction, or even sudden 
cardiac death. Myocardial infarction is chief among these diseases as it affects 
approximately 735,000 Americans each year and is one of the leading causes of death 
associated with cardiovascular diseases1. There are many factors that influence a patient’s 
risk for developing coronary artery disease (CAD), in which there is damage to the 
arteries supplying blood, oxygen and other nutrients to the heart that become unable to 
function properly. These factors include age, gender, family history, and diet1. As a 
patient gets older, there is a higher risk of damaging and narrowing of the arteries as 
plaque may build up in the arteries over time leading to the development of CAD. Men 
typically have a higher incidence of coronary artery disease that may be attributed to 
difference in hormones between men and women2. Family history has a significant 
influence, as a patient may be genetically predisposed to develop a coronary disease if 
their parents experienced coronary failure. A patient’s diet can contribute greatly to the 
development of a coronary disease as foods that have a high trans-unsaturated fat 
composition are easily packaged into low-density lipoproteins and can be readily 
deposited on the walls of arteries causing narrowing of the artery3. Finally, smoking is a 
risk factor directly linked to coronary disease in that nicotine can cause constriction of 
blood vessels and carbon monoxide can damage the endothelial layer of blood vessels 
leading to atherosclerosis4.  
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 Atherosclerosis is the first step in the development of a myocardial infarct and is 
characterized by the thinning of the arterial walls by the buildup of fatty plaque leading to 
ischemia of the ventricular wall of the heart. An occlusion of this kind may constrict the 
vessel at this point as a thrombus, or may occlude the vessel more distally with the 
formation of an embolism. The first step in atherosclerosis involves an irritant damaging 
the endothelial layer of the coronary arteries.  These irritants include accumulation of 
low-density lipoproteins, toxins from cigarettes, or from high blood pressure. Damage to 
the endothelial layer in the tunica intima breaches the non-thrombogenic surface of the 
endothelium and leads to an accumulation of low-density lipoproteins (LDLs) into the 
tunica intima. LDLs act to package cholesterol and fat in order to deliver the nutrients to 
specific cells in the body and travel through the bloodstream. After LDLs infiltrate the 
tunica intima, macrophages are attracted to the non-thrombogenic surface caused by the 
endothelial damage and begin to engulf the LDL particles that have infiltrated the blood 
vessel wall. Macrophages are attracted to the LDLs when the lipoproteins become 
oxidized by reactive oxidase species such as NADPH oxidase. The oxidation of the LDLs 
activates macrophages to the site of accumulation and they begin to ingest the LDLs. The 
macrophages eventually die and become giant foam cells that combine with the 
remaining oxidized LDLs and form fatty streaks in the artery. The fatty streaks become 
encapsulated by the smooth muscle cells from the tunica media to contain the fat 
accumulation and create a fibrous cap containing collagen and elastin. Finally, the 
smooth muscle cells begin to lay down calcium crystals such that the fibrous cap 
becomes rigid and the artery assumes a stiff nature with reduced flexibility5. Accordingly, 
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the protruding fibrous cap significantly reduces the internal radius of the blood vessel 
resulting in either increased blood pressure or complete occlusion of the vessel. The latter 
case will constrict blood flow to the heart, a phenomenon known as ischemia, and deprive 
it of receiving nutrients and necessary gas exchange. The restricted blood flow to the 
heart from the coronary vessels causes hypoxia of the ventricular wall tissue and can 
ultimately lead to necrosis of the myocardium and thus MI.  
Figure 1.3 The accumulation of plaque on an affected artery showing the narrowing effect of atherosclerosis. 
Image taken from  www.nhlbi.nih.org 
Insufficient blood flow to the heart results in an ischemic cascade in which there 
is reduced oxygen to the heart tissue. A hypoxic event downstream of the occluded 
coronary artery may result in cardiomyocyte necrosis in which the cells of the affected 
ventricular wall die and cease to conduct an electrical signal. Cardiac muscle necrosis 
during a myocardial infarction results in a large scale loss of cardiac myocytes that may 
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be on the order of one billion cells. Following this large scale loss of cells, the 
myocardium begins to develop functionally inferior scar tissue that mimics the native  
myocyte mechanics but introduces a variety of other complications to the patient. 
 
Figure 1.4 :Animation depicting coronary artery stenosis and subsequent myocyte necrosis and scarring. Image 
taken from www.surgery.ucsf.org 
 
Specific biochemical signals are released after necrosis that function to initiate a 
cascade to aide in repair of the tissue by recruiting collagen from myofibroblasts in the 
granulation tissue as well as fibroblasts from the healthy myocardium6,7. There are 
several time points that must be considered when examining the biomechanical properties 
of post infarct tissue namely during early and late remodeling. The early remodeling 
phase defined as the time up to 72 hours after infarction is characterized by a 
phenomenon known as infarct expansion. Infarct expansion occurs after the first few 
hours of myocyte necrosis and is described as the elongation and thinning of the infarct 
tissue resulting in an increase in elasticity as well as an increased risk for tissue tearing8. 
Healthy ventricular tissue and early infarct tissue exhibit significant elastic behavior but 
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an increase in the presence of the extracellular matrix component, collagen, in the infarct 
expanded tissue causes it to experience a more compliant behavior than healthy 
ventricular tissue. This increase in elasticity of the early infarct tissue can have 
detrimental effects on the health of the patient, as less stress is required to act on the 
ventricle wall during contraction to initiate a ventricular aneurysm or rupture and 
significantly increases the risk of such pathologies. A decrease in the thickness of early 
infarct tissue is a direct cause of the decrease in the tear threshold of the infarct scar, the 
maximum force that is achieved prior to the initiation of tearing. A study performed by 
Conelly8 examined the left ventricular walls of rabbit models for ventricles undergoing 
induced myocardial infarction as well as healthy ventricles for one week. They analyzed 
the results of myocardial infarction on the tearing threshold and wall thickness for both 
cases. It can be seen that that the tear threshold of early infarct tissue (less than three days 
after the infarct) is less than that of native tissue and that the force required by the heart to 
cause rupture is significantly less for the early infarct tissue. Additionally, it is obvious 
that the thickness of infarct tissue is significantly less than native myocardial tissue for 
the duration of the study.  
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Figure 1.5. B) Force required to initiate tear days after infarct
C) Ventricular wall thickness days after infarct .Images from Connely study [8]
During the phase known as late remodeling following myocardial infarction, the 
tissue exhibits larger stiffness than the native myocardium due to an increase in cross 
linked collagen. The late remodeling phase is defined as the time point after early 
remodeling (after three days post infarct). In the early phase, the tissue is more vulnerable 
to forces that can cause distortion but after this phase, the scar becomes much more 
resistant to additional deformation9. It is apparent that after the three day time point, the 
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maximum force required to initiate a rupture increases as time after infarction progresses. 
This is a direct result of the cross-linking of collagen in the infarct scar that functions to 
reduce the elasticity and increase the stiffness of the remodeled tissue. A decrease in 
elasticity such as this decreases the risk for developing a myocardial rupture or aneurysm 
as the force required to initiate such pathologies is significantly greater than early infarct 
tissue. Ultimately, the presence of collagen at the site of the infarct that replaces the 
native cardiomyocytes can cause interference with the electrical activity of the heart, as 
collagen is not considered an electrically excitable tissue.  The scar tissue can cause 
irregularities in a heart’s contraction sequence that can lead to arrhythmia or fibrillation 
of the muscle cells10. 
Following the scar formation phase of myocardial infarction, the heart has 
reduced output efficiency, as the necrotic center of the infarct can no longer efficiently 
meet the demands of cardiac output. Since the collective demand for blood to the cells of 
the body does not deviate after myocardial infarction, the ventricle must increase its 
workload to make up for the lowered output of the diseased ventricle. Just as skeletal 
muscles increase in size when an increased load is applied to a joint, the myocardium 
must deposit more muscle to facilitate the increased demand on the heart to adequately 
move nutrients throughout the body. This hypertrophic event will normalize the wall 
stresses in the heart and allow it to supply the body with the necessary volume of blood, 
but may lead to cardiac dysfunction and overall heart failure11. Myocytes comprise of 
two-thirds of the tissue volume of the myocardium but 70% of the cells in the 
myocardium are fibroblasts that synthesize ECM components. Ventricular remodeling 
 14 
not only includes cardiomyocyte hypertrophy but also the proliferation of fibroblasts in 
the myocardium. Phenotypic changes of the fibroblasts to myofibroblasts have also been 
observed and are considered to be a major contributor to the deposition of additional 
collagen leading to the stiffening of the heart wall and ultimately heart failure. 
 
1.3 Current Therapies 
Currently, the only completely curative treatment for myocardial infarction and 
subsequent heart failure is whole organ transplantation. Heart transplantation is severely 
limited in supply. It is estimated that nearly 5,000 heart transplants are performed each 
year worldwide with nearly 50,000 people on the waiting list as candidates for the 
procedure12. For the approximately 735,000 people who undergo myocardial infarction 
every year in the United States, there is not adequate donor supply should a significant 
number of these patients undergo heart failure. As the number of cases per year continues 
to grow, the prospects of having an adequate number of donor hearts to meet the 
increasing demand does not look promising. 
 The current gold standard for treating coronary occlusion and preventing 
significant necrosis of the myocardium is by percutaneous coronary intervention (PCI). 
For this procedure, the occluded coronary artery is treated by feeding a deflated balloon 
catheter into the artery and inflating it at the occluded site. The balloon reopens the 
stenotic artery so that the myocardium can be revascularized to prevent any further scar 
formation. Often, an expandable stent is placed to prevent further blockage of the artery 
and permanently hold open the vessel. It is estimated that the onset of necrotic events 
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occurs after one to two hours following ischemia. Current door-to-balloon times for 
hospitals admitting patients experiencing myocardial infarction symptoms have a 
standard time of 90 minutes and many facilities are ranked based on this metric13. 
Although 90 minutes is a very quick turnaround for patients to prevent myocyte necrosis, 
there is still some risk of significant myocyte death if the patient did not notice the 
symptoms fast enough or if the door-to-balloon time takes longer than the benchmark 
time. Inevitably, patients will experience some necrosis in the myocardium following an 
ischemic event.  
 
 
Figure 1.6 Depiction of a balloon catheter traveling along the coronary artery and depositing an expandable 
stent to force open the stenotic artery. Image taken from www.medtronic.com 
 
 Another treatment option available to patients undergoing myocardial infarction is 
a process known as coronary artery bypass grafting (CABG). In this procedure, a 
cardiologist removes a healthy vein from the patient’s own body to create an anastomosis 
bypass around a severely occluded coronary artery. This procedure is often used when a 
coronary artery is too occluded to conduct a PCI for risk of damaging the blood vessel. 
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Generally, the outlook for patients undergoing coronary artery bypass surgery is excellent 
and the 10-year patency for this type of treatment is favorable between 68% and 88% 
depending on the blood vessel used for treatment (Saphenous vein grafts versus internal 
mammary graphs respectively)14. However some studies have shown that CABG 
procedures result in a higher likelihood of causing a stroke than standard PCI15.  
 
Figure 1.7 : Schematic of a CABG procedure showing the use of a saphenous vein graft (left) and an internal 
mammary artery graft (right). Image taken from www.nhlbi.nih.gov 
 
Both PCI and CABG are effective at revascularizing the occluded coronary artery 
and reintroducing blood flow to the area of necrosis following myocardial infarction, but 
do not directly solve the issue of healing the infarct scar. These therapies will help the 
patient to avoid further myocyte death, but other therapies must be considered in order to 
fully repair necrotic tissue so that aneurysm formation, fibrillation, or heart failure do not 
occur as a result of MI. 
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 One method of treating an infarct scar in myocardial infarction patients is to 
completely resect the area of scar formation and reconstruct the ventricle such that the 
output efficiency of the ventricle is resumed and the ventricular volume is reduced to 
normal physiological levels. The surgeon first conducts a coronary artery bypass 
procedure to revascularize the infarct region of the ventricle using CABG. A mannequin 
ventricle is placed inside the diseased heart in order to act as a mold for the surgeon and 
optimize the ventricles dimensions. The ventricle is shaped accordingly and sutured 
together either directly or with a Dacron patch to prevent bleeding16. Recent studies have 
found that while ventricular reconstruction accompanied with CABG reduced the volume 
of the ventricle more so than with CABG alone, there was no significant benefit to the 
patients as there symptoms were no better than with CABG alone17.  
 Another method of treating patients with dilated ventricles resulting from 
hypertrophy after MI is treatment with angiotensin-converting-enzyme inhibitors (ACE 
inhibitors). In clinical studies it was found that ventricular remodeling can be favorably 
altered by ACE inhibitors if the patient is treated early (< 3 months post infarct) and 
results in significant ventricular volume reduction and decreased morbidity and mortality 
of patients with heart failure18. Other studies examined the use of beta blocker therapy in 
patients with congestive heart failure and found that the use of such a drug significantly 
reduced the volume of ventricles in a clinical study. The beta blocker acts by blocking 
neurohormonal activation that contributes to the progression of heart disease particularly 
in ventricular dilation. While the ejection fraction of blood from the heart is an important 
metric to consider the health of a CHF patient, the ventricular volume directly affects this 
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metric and should be considered as well. By blocking the actions of the sympathetic 
nervous system, the beta blocker drug, Carvidilol, significantly reduced the volume of the 
left ventricles in patients and is considered favorable for patient mortaility19. 
 Left ventricular assist devices (LVADs) offer advantages to heart attack patients 
by reintroducing blood flow from the failing ventricle to the aorta (or pulmonary artery 
for right ventricular failure). They are surgically implanted and mechanically pump blood 
in order to replace a completely necrotic or failed ventricle. LVADs can be used either as 
a bridge to receiving a donor heart for late stage heart failure patients or may be 
permanently implanted for the duration of the patient’s life. However, there are still 
concerns that LVADs increase the risk of the patient developing a thrombus, embolism, 
or infection. Patients must take anticoagulant medication for the duration of the time the 
device is implanted to reduce the risk of such pathologies.  
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1.4 Tissue Engineering Approach 
The current “Holy Grail” of myocardial repair following infarction is the potential use of 
a tissue engineered construct to be implanted over the infarct scar and regenerate the 
diseased tissue. This approach, if viable, would replace the need for donor hearts and 
reduce the morbidity of patients undergoing MI by replacing scar tissue with a patient’s 
own stem cells thereby eliminating the risk of donor rejection and immune response. 
Tissue engineering is a relatively young field with decades more research necessary in 
order to be a clinically relevant approach for treatment. However, there have been major 
advancements in the field and currently artificial skin and cartilage are approved by the 
FDA to be used in a clinical setting. These therapies only have a limited use in human 
patients and there is still considerable more research necessary to complete for this 
approach to be practical20. Tissue engineering involves the use of stem cells to 
 
Figure 1.8: A diagram of the tissue engineering paradigm showing the anticipated route to tissue regeneration. A 
biopsy of the patient’s own cells is cultured, seeded on an appropriate scaffold, introduced to various stimuli and 
implanted into the patient. Image taken from www.researchgate.net 
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differentiate into the cells that make up the target organ while maintaining the 
macroscopic shape of the target organ. A scaffold that acts to hold the cells in the desired 
shape is an important aspect of tissue engineering and can be composed of various 
materials that must mimic the function of native tissue in the body. Additionally a 
scaffold must be bioinert so as to not elicit an immune response and must degrade at the 
same rate as the stem cells lie down its own extracellular matrix. The scaffold acts as a 
medium in which the cells can hold their position while they differentiate into the cells of 
the target organ. After the stem cells become the target cell type, the scaffold may 
degrade as the cells construct a new, physiological ECM similar to a construction 
scaffold used in constructing buildings. The scaffold must provide adequate void volume 
to allow for vascularization of the newly formed tissue as to provide nutrients to the 
tissue21.     
The material used for a scaffold may vary depending on the application and the 
properties of the target tissue. The extracellular matrix of the target organ would be an 
excellent choice to use as a scaffold as it possesses the exact mechanical properties of the 
target tissue. A naturally occurring scaffold such as this could be obtained either from an 
allograft or a xenograft that has been sufficiently decellularized to eliminate the 
possibility of an adverse immune response. Typically, the decellularization procedure 
involves the rinsing of the tissue with a sodium dodecyl sulfate (SDS) detergent that 
functions to lyse the cells in the scaffold. One study found that SDS rinsing preserved the 
ECM architecture while effectively eliminating host DNA with the combined effect of 
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post-SDS nuclease treatment22. Significant issues may arise if the decellularization 
procedure does not completely remove all of the cells in a xenogeneic graft as a foreign 
body response to this kind of graft will cause the graft to fail. 
Another approach at scaffold materials that has been studied is the use of a 
hydrogel matrix to encapsulate cells in a semi-permeable membrane. The hydrogels are 
usually formed of alginate or from agarose22. Though these materials do have good 
biocompatibility, issues arise from the use of these materials due to limited capability to 
support cell attachment. 
  It is also important to consider mechanotransduction, the conversion of a 
mechanical stimulus into a chemical signal when designing a tissue-engineered organ as 
various stimuli can directly affect the differentiation of the stem cell into the desired cell 
type. For example, a tissue engineered vascular graft scaffold with seeded stem cells 
could be placed in a condition in which there is considerable pulsatile flow at 
physiological levels so that the mechanical stimulus of the fluid flow could stimulate the 
stem cells to differentiate into cells comprising the vasculature. The concept of applying 
various stimuli to a tissue-engineered system comprises the final design factor for an 
engineered tissue and is the main idea behind a tissue bioreactor.  
   The field of myocardial tissue engineering is in its infancy and there are several 
years of research still needed for therapeutic options to reach patients with myocardial 
infarction. Yet, there have been significant findings in the field that indicate only a few 
more advances are necessary for clinical application.  The first clinical trial (MAGNUM 
trial) aimed at testing the viability of stem cells implanted into the diseased myocardium 
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as well as stem cells seeded on a collagen scaffold implanted on the myocardium was 
carried out with promising results23. The researchers obtained bone marrow stem cells 
(BMCs) from the ilium bone and synthesized a 3 dimensional biodegradable collagen 
matrix to perform the cell seeding study. After standard coronary artery bypass procedure 
was performed, all of the patients received an intrainfarct implantation of the autologous 
BMCs with 250 million cells. The last 10 patients received the same number of cells 
seeded on the collagen matrix and sutured over the infarct area. The results indicate that 
there were no surgical complications for the entire procedure indicating that this 
procedure and all procedures that follow the same surgical technique are safe. Though the 
sample size was small, the results indicated that the combined approach of injected stem 
cells along with the implanted matrix appeared to make the heart repair more efficiently23. 
They reported that the cell seeded matrix was able to offer good structural integrity over 
the infarct scar and that the thickness of the ventricular wall after implantation was 
greater than the injection only group suggesting that the grafts may have helped to 
minimize ventricular remodeling and wall thinning. Although the results of the study did 
not suggest that the scar had been repaired or regenerated by the use of a cell seeded 
collagen matrix, it did indicate that the use of a matrix is not detrimental to the overall 
function of the infarct heart and may offer some therapeutic benefits.  
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Figure 1.9: Depiction of the two groups for the research study: the group receiving only injected BMCs (A) and 
the group receiving the cell seeded collagen matrix (B). Image taken from Chachques et al. [23] 
 
1.5 Chemical Stimulation of Stem Cells to Promote Cardiac Differentiation 
  The MAGNUM clinical study was a very important milestone in cardiac tissue 
engineering research as it demonstrated the efficacy of an implantable scaffold and its 
potential use as a medium for delivering stem cells to the myocardium for scar tissue 
repair. One avenue that has been looked into in the field of myocardial tissue engineering 
is the use of various chemicals to induce the differentiation of stem cells into 
cardiomyocytes for myocardial infarction repair.  
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Figure 1.10: Immuno-fluorescence staining confirming the presence of cardiac troponin T, cardiomyocyte 
specific cell marker. Image taken from Rangpapa et al. [25] 
 
A study by Rangpappa examined the use of 5-azacytidine to induce the 
differentiation of mesenchymal stem cells into cardiomyocytes25. 5-azacytidine is a 
chemical that mimics the cytidine molecule in DNA and affects DNA methylation which 
may contribute to controlling differentiation of stem cells into specific cell types. The 
researchers believe that as 5-aza demethylates the DNA in mesenchymal stem cells, they 
undergo a commitment to differentiate into cardiomyocytes. They cultured mesenchymal 
stem cells from rabbit adipose tissue and treated them with 5-aza at various 
concentrations (1, 3 6, and 9 uM) and were examined over a 2 month study. Only the 9 
uM concentration of 5-aza treated cells exhibited any kind of morphological change 
according to the data. After three weeks into the study, the 9 uM treated cells began to 
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beat spontaneously indicating the presence of functional cardiomyocytes. Additionally, 
the researchers conducted immunostaining to confirm the presence of specific 
cardiomyocyte markers including myosin heavy chain, alpha actinin, and troponin. As all 
markers were present, these results strongly correlated to cardiomyocyte differentiation 
of the MSCs. According to their data, their results suggested that fat-derived MSCs do 
have the capacity to differentiate into cardiomyocytes when treated with 5-azacytadine 
with the best evidence at 9 uM for 24 hours.  It may be possible to pretreat autologous fat 
derived MSCs to induce cardiomyocyte differentiation and to regenerate infarct 
myocardium. Since the MSCs in this study are fat derived, this approach has the 
advantage over other sources for acquiring stem cells as fat can easily be removed from 
the abdomen with rapid efficiency.   
Feng et al. (2009) examined the use of Suberoylanide hydroxamic acid (SAHA) 
on the differentiation of mesenchymal stem cells into cardiomyocytes and compares it to 
the often-used 5-azacytidine that has been shown previously to induce cardiomyocyte 
differentiation24. SAHA is described as a histone deacetylase (HDAC) inhibitor that 
functions to catalyze histone acetylation modifications26. Histone deacetylases are also 
used to balance the acetylation and deactylation of nucleosomal histones and have been 
shown to modulate chromatin function and structure as well as to regulate gene 
expression. Additionally, studies have shown that inhibition of histone deacetylases by 
suberoylanide hydroxamic acid leads to differentiation, cell cycle arrest, and apoptosis in 
tumor cells. Class II histone deacetylases that are inhibited by suberoylanide hydroxamic 
acid (SAHA) have been shown to play an important role in the development of cardiac 
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cells and the development of cardiac hypertrophy as well as the regulation of mesoderm 
cells into cardiomyoblasts27. The researches hypothesized that the use of SAHA in the 
culturing of mesenchymal stem cells could lead to cardiomyocyte differentiation in vitro. 
Mesenchymal stem cells were cultured and treated with various concentrations of SAHA.  
Real time PCR and western blotting were carried out to confirm the expression of 
specific cardiomyocyte markers including GATA-4, cardiac troponin T, and myosin 
heavy chain at different time points during differentiation. According to the data and 
(Figure 1.11) the addition of SAHA induced the differentiation of mesenchymal stem 
cells to cardiomyocytes as the chemical significantly enhanced the expression of GATA4, 
NKx2.5, and Mef2c, cardiomyocyte specific genes, by analyzing their mRNA content in 
the RT-PCR analysis. The researches carried out immunofluorescence staining for 
cardiomyocyte troponin T and myosin heavy chain and confirmed the presence of 
troponin T in all groups treated with SAHA. Additionally, there was no significant 
difference in the levels of cardiomyocyte specific genes between cells treated with 5-aza 
and SAHA and cells treated with SAHA alone. This study indicates that the effect of 
SAHA, the blocking of histone deacetylase that cause histone deacetylation, reverses the 
effect of blocking cell differentiation and ultimately enhances the differentiation of the 
stem cells into cardiomyocytes. It also indicates that the effect of 5-aza as a methylation 
inhibitor that has been used to differentiate stem cells into cardiomyocytes is not the 
dominant mechanism that determines cardiac differentiation of mesenchymal stem cells 
and that the effect of histone deacetylase inhibition is the dominant mechanism. 
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Figure 1.11: The bar graph indicates that TGF-b2 significantly increased the beating of the respective EB at 2 
and 4 ug/mL. Image taken from Kumar study [28] 
A study by Kumar describes the use of transforming growth factor-b2 to enhance 
the differentiation of cardiac myocytes from embryonic stem cells (ESCs). ESCs have the 
capacity to differentiate into all three embryonic germ layers and as such have the ability 
to differentiate into cardiomyocytes28. The capability of ESCs to generate 
cardiomyocytes offers great promise for stem cell therapy for patients with myocardial 
infarction but show limited differentiation when transplanted into infarct hearts. The 
study was conducted to examine the effects of TGF-b1, b2, and b3 isoforms on the 
stimulation of ESCs into cardiomyocytes to potentially improve the outcome of cell 
based therapies. The cells were cultured and formed into embryoid bodies and were 
treated with varying densities of TGF-b1, b2, and b3 (at 0, 2, 4, and 8 ng/mL). According 
to the data, the TGF-b2 growth factor significantly increased the proliferation of the 
embryoid bodies by as much as 65% as compared with the control groups. This differed 
significantly from the TGF-b1 and b3 treated cells whose embryoid proliferation did not 
significantly change from the control group. Additionally, the percentage of embryoid 
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bodies that were beating as well as the beating area per embryoid body were significantly 
higher for TGF-b2 treated cells than for either the control or the TGF-b1 or b3 treated 
cells. TGF-b2 treated cells showed a positive stain for yellow fluorescence protein that is 
driven by the presence of cardiomyocyte specific alpha-actinin promoter that was not 
present in any of the other groups and were elongated and larger in size more so than in 
other groups. These results indicate that TGF-b2 not b1 or b3 is successful in inducing 
cardiomyocyte differentiation in vivo and may be a viable chemical treatment in cardiac 
tissue engineering that can ultimately be used to treat patients with significant heart 
failure. 
1.6 Mechanical and Electrical Stimulation of Stem Cells to Promote Cardiomyocyte 
Differentiation 
  Several groups have investigated the idea of reproducing physiological stimuli 
present in the heart for the purposes of mimicking optimal conditions in the body in order 
to induce cardiac differentiation.  The Eschenhagen (2006) study demonstrated that by 
applying mechanical strain on engineered heart tissue, the constructs exhibited increased 
CM alignment, sarcoplasmic protein organization, and enhancement of contractile force 
generated by the constructs29.  The effects of electrical stimulation on a tissue-engineered 
construct have been studied extensively by many different groups with promising results. 
Several studies have shown that applying electrical fields to a myocardial tissue-
engineered construct with physiologically relevant parameters can encourage the 
development of electrical connectivity and excitability of cardiomyocytes, as evidenced 
by increased expression of cardiac specific connexin 43, lowered excitation thresholds, 
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and increased stimulus capture rates30.  Few groups have investigated the effect of 
applying both stimuli characteristic of the cardiac environment to a cell seeded construct.  
Even fewer groups have tested these stimuli within a bioreactor with carefully 
synchronized timing of electrical and mechanical stimulation in accordance with 
physiological parameters.  
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Chapter 2: Materials and Methods 
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2.1 Scaffold Preparation 
 Whole hearts were obtained from adult pigs at a local slaughterhouse. Following 
the harvest, the hearts were flushed with warm 50 mM EDTA through the left and right 
coronary branches via syringe to flush out any blood clots that may have formed and to 
prevent new ones from forming. Hearts were then cleaned of any residual fat by cutting 
using a standard surgical scalpel, cannulated at the aorta, plugged at the vena cavae and 
placed in the decellularization system (DCELL). Briefly, the system is comprised of  a 
series of pumps and reservoirs (Masterflex, Cole Palmer) that circulated 3.5 L of various 
solutions throughout the DCELL process. The inflow reservoir was elevated at 90 cm 
above the cannulated hearts and allowed to circulate via gravity at an approximate 
hydrostatic pressure of 80 mmHg.  A lower chamber collected flow through from the 
heart chambers and was circulated throughout the system via a Masterflex peristaltic 
pump.  30 mM EDTA in PBS at pH 7.5 was added to the system and circulated for 15 
hours. Next, DCELL chambers were cleaned and the hearts were treated with 1% w/v 
SDS (with 0.02% sodium azide for sterility) to effectively wash away cellular content in 
the hearts.  The solution was changed every 4 days and hearts were weighed after every 
solution change until the hearts appeared to be decelled or the recorded mass loss was at 
50%22.  Following SDS wash, the hearts were washed with distilled/deionized water 
(with 0.02% sodium azide) for 4 hours, then again for an overnight wash, followed by an 
additional 4-hour wash. The same wash process was repeated but with 70% ethanol as the 
solution followed by another water cycle.  A PBS washing cycle ensued followed by a 
RNAse/DNAse (Worthington Biochemical) at 720 munit each in PBS for 48 hours. A 
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final PBS wash was performed prior to storage in PBS with 0.02% sodium azide and 
0.001% protease inhibitor.  
2.2 Flexcell and Electrical Stimulation 
 A commercially available Flexcell system was modified to integrate mechanical 
and electrical stimulation of cells seeded on decellularized myocardial scaffolds, and to 
allow precise control of these two stimuli for physiological consideration.  Design inputs 
included: 1) A uniaxial tensile force application up to 140 mmHg to a cell-seeded 
construct, with the ability to control characteristics of the waveform 2) Electrical stimulus 
up to 2 V to seeded constructs with the ability to control other characteristics of the 
waveform 3) Coordinate timing of the delivery of these two stimuli to the construct to 
allow for variation in the waveforms 4) Conventional culture of seeded constructs in a 
standard incubator with standard media, and facilitate convenient changing of media 
every 2-3 days 5) A sufficient number of experimental replicates to achieve statistical 
significance among experimental groups in measured endpoints.  
A commercially available system sold by Flexcell International Corp. served as 
the basic component around which this platform was designed (Figure 2.1). The system 
was sold under the name FX-5000™ Compression System, and was comprised of a main 
controller housing with pressure regulators, valves, and transducers used to precisely 
control the flow of compressed air into a baseplate upon which four 6-well plates were 
attached (Figure 2.1 B and C). The bases of the 6-well plates were hermetically sealed 
against rubber gaskets on the baseplate by means of telescoping bolts that clamped the 
well plates to the baseplate (Figure 2.1 E). The system functioned by pumping 
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compressed air into the space beneath the baseplate and the well plates above, forcing the 
membrane at the bottom of each well upward (Figure 2.2 F). The result was that the 
membrane moved upward like an inflating balloon when air was pumped into the 
baseplate and returned downward to a flat position when air pressure was released. This 
movement was very similar to the motion of the left ventricular free wall during diastole 
and systole, and was used to simulate that. The accompanying Flexcell software was used 
to create a pressure waveform modeled after the left ventricular pressure waveform 
observed during the cardiac cycle (Figure 2.2 A). A pressure transducer was used to 
measure the real-time pressure applied to the silicone membrane, and the data was input 
into a custom-written LabView program. This program was designed to deliver an 
electrical pulse which was triggered when the pressure reading reached a specific value 
input by the user (Figure 2.2 A and C). In other words, the LabView program was used to 
tightly control the delivery of both mechanical and electrical stimuli to samples contained 
within the well plates. This fact allowed us to simulate the excitation-contraction 
behavior of cardiac muscle in an effort to expose hADSCs to proper physiological stimuli 
and induce their differentiation into CM. 
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Figure 2.1: Design of Flexcell system: A) Schematic illustration of main components of the Flexcell system. B) 
An incubator containing the modified Flexcell® system comprised of tubing, baseplate, and 6-well plates with 
silicone membranes pumps air into the baseplate shown in C, where E) telescoping bolts are used to seal the 
edges of F) modified 6-well plates against a rubber gasket. D) Flexcell controller (2 bidirectional, software-
controlled valves inside) and data acquisition (DAQ) modules, which collectively enable all measurement and 
output of physical signals in the system, are shown. 
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Figure 2.2: Detailed operation of Flexcell system: A) Screenshot of display from computer used to control the 
Flexcell system. The window at back left is the Flexcell software, running the programmed regimen and 
displaying pressure waveform data collected by the Flexcell controller’s pressure transducers. The window at 
front right is the LabView program, displaying pressure waveform data from a pressure transducer which was 
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tapped into the positive pressure line running to the Flexcell baseplate. This data was acquired by one data 
acquisition (DAQ) module and fed into the LabView program; this program triggered an electrical pulse, output 
by a second DAQ module, every time the pressure fell within a user-defined range (in this case, at the rising edge 
of each pressure wave). A, C) This trigger is illustrated by two virtual LEDs in the LabView display (dashed 
yellow ovals), which indicate the status of the pulse by lighting up with an “ON” or “OFF”. E,F) Pressure from 
air pumped into the baseplate (blue arrows in F) with 6-well plate sealed atop it causes upward deflection of the 
silicone membrane in each well. Scaffolds are shown in F with horizontal ends fixed in place at the sides of each 
well. When the membrane deflects upward under pressure, a resultant uniaxial tensile force (black arrows with 
yellow outline in E and F) is applied to the scaffold. F) Heat map illustration of the potential field and graph of 
electrical potential vs. position generated from a Comsol™ model based upon the well and electrode dimensions 
and the applied electrical pulse. The region of interest (R.O.I.), or the area of scaffold where the effects of 
mechanical stimuli and electrical stimuli will both be applied to seeded cells, is indicated with a dashed box. B, 
D) Auxiliary setup for plates receiving only electrical stimuli; these plates could not be kept in the same 
incubator as those receiving mechanical stimuli because said incubator was set at a higher temperature to offset 
the cooling effect of running compressed air through the baseplate. D) The LabView program responsible for 
delivering the electrical stimulus to electrical only plates; the characteristics of the pulse (amplitude, frequency, 
duration) were controlled to match those of the electrical pulse produce by the program in A and C. 
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2.3 Flexcell Experimental Setup 
 We determined that there were three factors that contribute to CM differentiation 
of hADSCs in our study: mechanical stimulation (M), electrical stimulation (E), 
properties of the scaffold with no external stimulation (S), and a combination of electrical 
and mechanical (EM).  Scaffolds for this study were prepared using the described 
DCELL procedure to prepare the tissue, which were then dissected into 2.0 x 3.8 cm 
rectangular segments.  The segments were then sheared using a scalpel to generate 1-2 
cm thick scaffold sheets to fit into the Flexcell plates.  Six sheets were prepared per 
Flexcell plate with four total plates for each experimental group (M, E, E+M, S) resulting 
in 24 total scaffold sheets to be tested. Sheets were washed three times (1 h, 3 h, 1 h) in 
PBS at pH 7.4 before being sterilized with 0.1% paracetic acid (30 min, 1 h).  Each sheet 
was incubated in DMEM with 10% FBS overnight then another 2 h at 37 °C after media 
was removed in order to slightly dehydrate the sheets.  Dehydrated scaffolds were 
thought to allow better penetration by cells than if it was fully hydrated.  After scaffold 
sheets were secured in the inserts, a hADSC cell suspension was injected at random 
points near the center of each sheet with a total of 3.1 x 106 cells onto each sheet 
(Invitrogen passage 5 hADSCs).  Seeded scaffold sheets were incubated for 4 hours 
without additional media in order to allow the cells to adhere to the scaffold. After this 
time, each well was brought up to 6.5 mL of media (DMEM with 10% FBS) and 
incubated for another 20 hours statically.  Each scaffold construct had a working 
rectangular area of 3.6 cm2.  The working area or region of interest (R.O.I) was subjected 
to a cyclic pressure waveform (0 to 120 mmHg amplitude in 350 msec with 450 msec 
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static at 0 mmHg) and a 5 V, 2.78 V/cm2, 20 msec width, square wave electrical pulse 
applied at the rising edge of every pressure wave similar to the conduction rhythm of the 
heart (only (E) and (EM) received electrical stimulation, (M) received only pressure 
stimulus, (E) did not receive pressure stimulus).  This setup ran for 21 days and the media 
was changed every 2 days.   
2.4 Differentiation of hADSCs using 5 – Azacytidine 
 The effects of 5-aza-2-deoxycitidine (AZT) were examined in the study to 
determine if differentiation of hADSCs towards CM was possible using this chemical 
agent.  1.0 x 106 hADSCs of passage 3 were cultured and seeded onto 3 standard corning 
6-well plates at 50,000 cells per well in DMEM with 10% FBS. Three wells of one AZT 
treated 6 well plate were designated for protein analysis and the remaining 3 were to be 
used for RNA retrieval.  The second 6-well plate (all AZT treated) was designated for 
only Immunofluorescence staining. The third six-well plate was a control group with no 
AZT treatment and was split into 3 groups in which 2 wells were set aside for each of the 
3 analysis techniques just described. In accordance with values from literature, 10 uM 
solution of AZT was diluted from stock Sigma-Aldrich 100 mg 5 azacytidine and placed 
over 2 seeded 6WPs representing the treated group (AZT).  Cells were incubated for 24 
hours and AZT was removed following this time.  All cells were then cultured for 7 days 
where the media was changed every 2 days.  
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2.5 Co-Culture Study with hADSCs and hESCs 
 The effect of a dual culture with hADSCs and human embryonic stem cell derived 
cardiomyocytes (hESCs) from Cytiva was examined.  HESCs were thawed in a 37°C 
water bath and were deposited drop-wise into a 50 mL conical tube into 1mL of 
RPMI/B27TM medium.  All wells were pre-treated with 1 mg/mL of fibronectin (sigma-
aldrich) for 2 hours in an incubator to promote cell adhesion.  Two wells contained only 
hADSCs, two wells contained only hESCs, and two wells contained a 2:1 ratio of 
hADSCs : hESCs.  150,000 cells were cultured in each well.  Additionally, the same 3 
groups were scaled down and seeded on Nunc® Lab-Tek® Chamber Slides™ with 8 wells 
available for each slide to be used for Immunofluorescence staining.  The cells were 
seeded with a density of 20,000 cells per well and the same 2:1 ratio for the AE group.  
Media was changed every 2 days to ensure cell survival.   
2.6 3D Cell Spheroid Study 
 In an effort to promote even greater cell-cell signaling, and order greater cell 
differentiation, three-dimensional cell spheroid constructs were used.  For this study, it 
was desired to a 3D environment for cell growth.  A gel cast was prepared to force the 
cells into the desired shape. The 1% w/v agarose gelatin solution in water was boiled.  
For complete dissolution, the gelatin mixture was placed on a hot plate and set to 70°C 
with a stir bar for continual agitation under the cell hood.  A container of ice was used 
upon which the Sigma-Aldrich 12 36TO 3D Petri Dish® mold was placed. To form the 
gels, 500 uL of agarose gel was deposited onto each mold and placed over the ice to 
initiate rapid cooling.  After 2 minutes, the rubber molds were flexed and the new cast 
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was removed and placed in a 12 well plate along with 2 mL of DMEM and 10% FBS for 
15 minutes in an incubator.  This was repeated twice to completely equilibrate the gel.  A 
total of 12 casts were made using this technique.  Media was aspirated from the gels and 
hADSCs were seeded at a density of 1.08 x 106 cells per gel for a density of 30,000 cells 
per sphere and 36 spheres per gel cast.  While the cells were forming into their desires 
shape, a 10 uM solution of AZT was made and half of the gels were treated for 24 hours.  
Following a 3 day settling period, the cells had visibly conformed into spherical 
structures and were ready to be seeded onto well plates.   
 Following the incubation and sphere-forming step, the constructs were ready to be 
seeded onto Flexcell-compatible six well plates and be subjected to a mechanical 
stimulus.  The gel casts were aspirated and flushed with fresh media in order to remove 
the spheroids.  With gentle agitation and rinsing upside down, the spheroids were 
removed and collected in a 2mL micro centrifuge tube.  The AZT treated spheres were 
placed evenly in 1 six well plate and the untreated control group was in the other six well 
plate (approximately 432 spheres total and 36 spheres per well).  Flexcell 6WP were 
placed in the loading station as shown in Figure 2.3 and adhered to the station with 
petroleum jelly and held firmly in place with loading screws.  The baseplate is connected 
via vacuum tubing to the FX5K™ Tension FlexLink®, a remote tension/compression 
unit that is connected to a desktop computer. The pressure waveform was consistent with 
the previous experiment. 
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Figure 2.3: Flexcell culture plates mounted in the loading station 
 
 
Figure 2.4 Flexcell FX-5000 setup 
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2.7 3D Spheroid Co-Culture Study 
 The hESCs and hADSCs were cocultured under conditions similar to the previous 
3D cell spheroid study.  The method of producing the gel casts was identical to the 
previous study except only three casts were used.  The hADSCs used in this study were 
tagged fluorescently using a Vybrant® CFDA SE Cell Tracer Kit.  A 10 mM 
concentration of CFDA stock solution was made by dissolving contents of kit-included 
Component A and DMSO (Component B) and then diluted to a working concentration of 
0.20 uM.  After thawing frozen hADSCs, the cells were centrifuged and suspended in 
prewarmed CFDA working solution.  Cells were re-pelleted and resuspended in medium 
before being seeded.  The same density of cells per spheroid was used at 30,000 and a 2:1 
ratio of hADSCs to hESCs was also implemented.  Following spheroid formation after 6 
days (spheroids were slower to form) the casts were flushed with media and 
approximately 9 spheroids were deposited in each well of a 12 well plate according to the 
3 groups (hADSC only, 2:1 co culture, and hESC only).  The 12WP was divided into 3 
wells per group being utilized for immunofluorescence staining and 1 well per group 
being utilized for protein harvesting for use in western blotting.  RPMI media was 
changed every 2 days for the duration of the study of 7 days. 
Immunofluorescence Imaging and Cell Staining 
 At the conclusion of these studies, Immunofluorescence imaging was performed 
in order to examine any cardiac specific markers that could have been expressed by the 
cells in each study.  At the conclusion of the studies, well plates were washed with PBS 
and fixed with 4% paraformaldehyde (PFA) for 20 minutes at room temperature.  PFA 
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was aspirated and the cells were rinsed with PBS 3 times before being permeabilized with 
0.3% triton in PBS for 10 minutes at room temperature.  The cells were then blocked with 
5% bovine serum albumin and 0.05% triton in PBS for 1 hour.  Cells were then treated 
with primary antibodies (Alexa Fluor®) diluted in blocking solution 1:1 for 2 hours and 
placed on an orbital shaker at manufacture suggested dilutions that varied with each 
antibody.  Primary antibodies were saved for future use and wells were rinsed with PBS 3 
more times to ensure all primary antibodies were washed off.  Secondary Alexa Fluor® 
antibodies were put over the cells 1:1 in blocking agent at 4uL/mL and left for 1 h at 
room temperature.  Stock DAPI solution was diluted 1:1000 and placed over the cells for 
5 minutes before imaging on the microscope using the Axiovision® software.  Images 
were taken of each well at 10X magnification using corresponding fluorescent light filters 
for the tagged antibodies as well as the DAPI stained nuclei.  Cardiac markers that were 
tested included antibodies of desmin, cardiac myosin heavy chain, troponin T, and alpha 
actinin.  
2.8 BCA and Western Blot Protein Analysis 
 The amount of protein in each sample must be normalized such that the same 
amount of protein is being compared for each group.  In order to initially quantify the 
amount of protein in the sample, a bicinchoninic acid (BCA) assay (Pierce) was used on 
the samples from both 2D cell studies.  BCA assay was run by first pipetting 5uL of each 
dilution of the stock protein solution in a 96 well plate to generate a standard curve.  All 
testing samples were then pipetted in 5 uL each and 200 uL of the working solution 
included in the kit was added to each well.  After 30 minute incubation the plate was read 
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by a plate reader and the intensity of the color produced by the reaction of the working 
solution and the protein was recorded for each sample and the protein standards.  
Following the generation of a standard curve, the protein was then quantified using the 
curve formula.  Preparing for gel electrophoresis included calculating the necessary 
volume of each sample such that the amount of protein was the same for each sample at 
20 ug.  Samples were loaded in centrifuge tubes along with a corresponding amount of 
reducing buffer and 5 uL of β-mercaptoethanol and placed in boiling water for 5 minutes.  
Samples are then loaded in the electrophoresis gel supplied in the BM 
Chemiluminescence Western Blotting Kit (Roche) with 50 uL in each well.  After 
electrophoresis was conducted at 200 V for 35 minutes on ice, the gels were removed 
from their plastic chambers and treated with transfer buffer before running them again in 
an electrophoresis module to transfer the protein to a PVDF membrane for anaylsis.  
Blots were blocked then labeled with primary antibodies of desmin, cardiac myosin 
heavy chain, troponin T, and alpha actinin and detected using supplied secondary 
antibody.  Blots were imaged on a BioRad ChemiDoc system and bands were read for 
relative intensity and molecular weight.  
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Chapter 3: Results and Discussion 
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3.1 Flexcell: hADSC Scaffold Seeded Differentiation Study - Decellularization 
 During this process of whole heart decellularization, termed perfusion 
decellularization, hearts were examined to determine whether they could be deemed fully 
DCELLed.  When the hearts were weighed after each SDS wash step, images were taken 
to determine the extent of DCELL for each heart and if the hearts needed further washing.  
According to a study by Jason Schulte, scaffold color and mass loss are indicative of 
muscle cell removal and must be examined in each washing step of perfusion SDS 
DCELL22.  Approximately 50% of the total mass removed from the hearts would indicate 
almost complete muscle cell removal or if the color of the hearts became light and had 
the appearance of complete cell removal.  According to Table 1, our hearts did not 
converge to the maximum weight loss of the Schulte study, as the final weight of all of 
the hearts did not exceed 42% and a minimum of 15.6%.    
 
Figure 3.0:  Initial weight and weight after each SDS wash step for the 3 hearts.  Target weight calculated from 
the Schulte study and total weight loss percent calculated from initial weight and final weight before ethanol 
wash. 
 Although the hearts did not reach the target weight loss threshold, 
macroscopically, the hearts appeared to be decelled and void of most cellular debris.  
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Figures 3.1 – 3.2 show the progression of the hearts from shortly after they were obtained 
from the slaughterhouse through the 7 SDS wash steps.   
 
A 
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Figures 3.1 – 3.2:  A) Image of fresh porcine hearts before washing. B) Hearts after cannulation and first SDS 
wash after 4 days. C) After 5th SDS wash step, the hearts appear to become lighter as cellular debris is removed. 
D) Visibly DCELLed hearts after 7 washes in SDS. NOTE: heart 1 was washed twice more to ensure DCELL 
but never became as discolored as hearts 2 and 3.  
 
 
  
D 
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Indeed, the hearts were ready to continue DCELL to be used as myocardial scaffolds.  
Following complete DCELL, histological analysis was conducted to determine if the 
scaffold was still intact and that no nuclei remained of the native tissue.  Hemotoxylin 
and Eosin stains in Figure 3.4 confirmed that there were no nuclei remaining in the 
scaffold and that small voids remained where myocytes were removed.  Results from this 
study follow the conclusions from the Schulte study, as the integrity of the extracellular 
matrix remained intact.  As a result, these acellular scaffolds most likely retained laminin, 
fibronectin, and collagen IV as well as the native microvasculature necessary for cell 
survival if implanted.  Indeed, the scaffold is well suited for repopulation with stem cells 
as the cell voids are ideal cell niches. 
 
Figure 3.3: H&E stain of native heart tissue taken before any washing steps 
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Figure 5.4: H&E stain taken after complete DCELL process.  Presence of voids in the scaffold indicates 
complete DCELL as all native cells have been removed.  Intact collagen indicates that the scaffold was not 
destroyed during the DCELL process. 
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3.2 Flexcell: hADSC Scaffold Seeded Differentiation Study – Cell Seeding and 
Stimulation 
 Following heart decellularization and scaffold preparation, cells were seeded on 
scaffolds and placed in the Flexcell bioreactor for 3 weeks.  Upon the conclusion of the 
study, the scaffolds were either fixed and used for histological staining, or were 
pulverized and proteins were harvested.  The markers studied in this experiment play 
crucial roles in the function of cardiomyocytes and 4 major muscle proteins were 
investigated.  Desmin is a Class III intermediate filament in muscle cells that connect 
myofibrils to each other and to the plasma membrane from the pereiphery of the Z-line 
structures.  This protein helps maintain the structural integrity of the muscle cell during 
contraction and aids in force transmission and load bearing31.  Troponin T is the 
tropomyosin binding subunit of the troponin complex found near the heads on myosin 
filaments which normally impedes the binding of actin and myosin unless the complex is 
bound with a calcium ion32.  This is an important intermediary mechanism for sliding 
filament muscle contraction in muscle cells of skeletal and cardiac nature.  Sarcomeric 
alpha actinin (aactinin) is a protein present in cardiac muscle cells that anchors 
myofibrillar actin filaments to intracellular structures.  Beta myosin heavy chain (BMHC) 
is a muscle specific protein that ultimately forms the bulk of the thick filaments in 
cardiomyocytes.   They play a major role in muscle contraction by hydrolyzing ATP and 
drive the shortening of sarcomeres as myosin travels along actin filaments.  The presence 
of this protein in tissue-engineered constructs would certainly confirm that the cells are 
forming into a muscle-like morphology.   
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 A histological stain of Hemotoxylin and Eosin (H&E) was carried out on the 
tested scaffolds of the M (mechanical stimulus only), E (electrical stimulus only), M+E, 
S (static with no stimulation) groups, and NC (negative control as hADSCs cultured on 
well plates with no scaffold).  Due to repeated difficulties in histological staining, only a 
select few images were examined.  
 
 
 
 
 
 
A 
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Figure 3.5: H&E staining of select samples that demonstrate cell clumping instead of infiltration into the 
scaffold. A) Group M2 at 10X magnification with cells found only on the periphery of the tissue. B) and C) 
Group M3 at 10X magnification showing the large cell bolus. D) Group M4 showing a similar result as the other 
images with a large cell clump on the scaffold periphery 
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Figure 3.5 A-D show that the cells did not infiltrate the scaffold as intended and 
instead formed into boluses at various points around the tissue or into distinct sheets of 
cells.  Figure 3.5 B and C show an extreme case in which the cells formed large 
conglomerates instead of infiltrating the tissue into the intact cell niches.  Figure 3.5 D 
shows a similar case in which the cells appear to form into a large cell sheet rather than 
infiltrating the tissue.  Obviously, by examining these images, the tissue-engineered 
scaffolds do not appear to form into a cardiac like tissue morphology, as cell infiltration 
into the scaffold is paramount.  Western blotting was carried out and the 4 main cardiac 
markers were tested to confirm their presence in the tissue-engineered constructs. 
 
Figure 3.6: Western Blot intensity values for each group comparing the intensity of BMHC. A * indicates 
statistical significance by ANOVA analysis between tested groups (E), (M) and control (S) and negative control 
(NC).   
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Figure 3.7: Western Blot intensity values for each group comparing the intensity of Aact. A * indicates statistical 
significance by ANOVA analysis between tested groups (M) and control (S) and negative control (NC). No 
statistical significance between stimuli applied groups EM, E and M. 
  
Figure 3.8: Western Blot intensity values for each group comparing the intensity of Desmin. A * indicates 
statistical significance by ANOVA analysis between all stimuli receiving groups as well as the Static group with 
the negative control (NC). No statistical significance between stimuli applied groups EM, E and M or with S. 
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Figure 3.9: Western Blot intensity values for each group comparing the intensity of Troponin T. A * indicates 
statistical significance by ANOVA analysis between all stimuli receiving groups and the negative control (NC) 
and Static (S) groups. No statistical significance between stimuli applied groups EM, E and M.   
 
According to the data, all groups subjected to an external stimulus expressed cardiac 
myosin heavy chain and had statistical significance with the control groups of cells 
seeded on a scaffold with no stimulus (S) and the negative control group of hADSCs on a 
standard 6WP (NC).  Indeed, high expression of this protein with statistical significance 
shows that these cell constructs have developed into the cardiomyocyte phenotype to 
some degree by the induction of external stimuli.  Presence of myosin heavy chain is 
indicative of the formation of muscle thick filaments, a crucial protein for muscle cell 
contraction.  Only the groups of E and M had statistical significance with the controls 
suggesting that the combinatorial stimulation of the electric field and mechanical strain 
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(EM) may not have been as effective as treating the constructs with a single stimulus first 
although this is not statistically proven in the data.  
Alpha actinin (aact), the muscle specific protein that functions as an anchor for 
actinin thin filaments was present in all stimulated groups but the only statistical 
significance observed was between the mechanical only stimulus group and the two 
control groups.  Obviously, it can be determined that the induction of an external stimulus 
has an effect of producing muscle specific proteins in cell seeded myocardial scaffolds. 
By the process of mechanotransduction, the cells experience conditions similar to 
physiological conditions in a native heart and are coaxed into becoming cardiomyocyte-
like cells.  Perhaps the formation of these cardiac proteins is one of the first steps in the 
process of hADSC differentiation into the cardiomyocyte phenotype.  This is further 
demonstrated with the presence of troponin T proteins in the seeded constructs, as there is 
statistically significant expression between all the stimulated groups and the two control 
groups.  Presence of troponin T is indicative of the formation of muscle contraction 
complexes along with MHC suggesting that at least a portion of these cells were 
potentially becoming cardiomyocyte-like.  
All groups in the Flexcell system showed expression of the muscle specific 
Desmin protein as well as the cells of the negative control.  In fact, there was 
significantly more expression of Desmin in the negative control group compared to the 
stimulated groups.  This intense expression of Desmin in untreated hADSCs is consistent 
in studies conducted later in which Desmin is present in all groups whether treated with a 
stimulus or not.  In a study by Wallace, desmin was found to be present during 
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immunofluorescence staining of cardiac fibroblasts and that the cells contained low but 
significant concentrations of the protein and that is likely forms a copolymer with 
vimentin33.  The positive expression of desmin in the negative control group could be a 
result of hADSC differentiation towards a cardiac fibroblast type cell in the well plates.   
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3.3 Two Dimensional Cell Differentiation Study– 5-Azacytidine Treatment 
 The next study following the Flexcell bioreactor experiment was aimed at 
discovering if a chemical compound could induce hADSC differentiation on its own and 
experience some capacity of cardiac differentiation.  5-azacytidine was the chemical in 
question to be tested as various groups have shown its ability to induce the differentiation 
of mesenchymal stem cells towards cardiomyocytes35.  This chemical is a DNA 
demethylator, in brief, AZT inhibits the action of DNA methyltransferase enzyme, 
leaving portions of the genome unmethylated and therefore more accessible to binding by 
transcription factors that may be upregulated as a result of signaling cascades activated 
by changes to the substrate or the application of other stimuli.  Additionally, it is believed 
that as 5-aza demethylates the DNA in mesenchymal stem cells, they may undergo a 
commitment to differentiate into cardiomyocytes25.  With this in mind, the objective was 
to eventually incorporate this chemical component of stimulation along with the 
mechanical and electrical stimulation procedure outlined in the Flexcell experiment to 
further coax cells to a cardiomyocyte phenotype.  Upon completing a 7-day culture on 
standard 6WPs, Aza treated cells were imaged using immunofluorescence to examine the 
cardiac markers discussed before. Images 5.10 – 5.12 show the expression of desmin, 
troponin T, and myosin heavy chain on cells treated with aza and on the control, 
untreated groups. 
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Figure 3.10: All cells stained for Desmin in green and nuclei in blue (DAPI) A) hADSCs treated with 5-
Azacytidine image taken at 10X magnification. B) Aza treated cells at 20X magnification, C) Aza treated cells at 
40X magnification. D) Control hADSCs with no chemical treatment at 10X magnification. 
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Figure 3.11: All cells stained green for MHC and blue for nuclei. A) hADSCs with Aza treatment at 10X 
magnification, B) at 20X magnification. C) non treated hADSCs control group at 10X and D) non treated 
hADSCs at 40X magnification 
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Figure 3.12: All cells stained green for Troponin T and blue for nuclei. A) hADSCs with Aza treatment at 10X 
magnification, B) at 20X magnification and C) non treated hADSCs control group at 10X. 
  
 
Figure 3.13:  Western Blot data for AZT treated hADSCs and control hADSCs cultured on 6WP.  There is no 
statistical significance in the data with n = 3. 
C 
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 In addition, western blot analysis was carried out to examine the protein content 
of the treated cells.  The same three cardiac markers were tested and results are illustrated 
in Figure 3.13.  According to the IF images, desmin was present in the AZT treated 
groups and showed very distinctive expression but was not as apparent in the control 
group that did not receive azacytidine treatment.  According to the western blot data 
showing the intensity values of expressed desmin, there was no statistical significance 
between the Azt treated group and the control group suggesting that stimulation with Azt 
does not have an apparent effect on the development of desmin on hADSCs.  These 
results are supported by the previous study in which desmin was found on untreated 
hADSCs that was designated as a negative control.  Again this may be a result of 
unintended differentiation of hADSCs toward a cardiac fibroblast cell type.  
 Immunofluorescence staining of treated and untreated groups with MHC showed 
that AZT treated groups did not express MHC in any capacity but untreated hADSCs 
showed a strong, positive expression of the cardiac thick filament protein.  However, 
according to the western blot, the control group did not express MHC along with the 
treated group.  This anomaly may be explained by unintended differentiation of the 
control group towards cardiomyocytes in the well in which it was imaged but not in the 
well in which the protein was harvested even though culture methods were consistent.   
Staining for Troponin T did not result in any expression in either group and was 
confirmed by the western blot that showed no intensity for the corresponding molecular 
weight.   
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3.4 Two Dimensional Cell Differentiation Study– hESCs Cocultured with hADSCs 
 The following study was aimed at examining the possibility of inducing cardiac 
differentiation of hADSCs by culturing them in direct proximity with human embryonic 
derived cardiomyocytes.  Human embryonic stem cells (hESCs) have the capacity to 
differentiate into all three germ layers and have the strongest capacity to differentiate into 
cardiomyocytes.  Previous studies have found that by forming hESCs into cell aggregates 
known as embryoid bodies (EB), they upregulate specific cardiac genes such as troponin, 
MHC and alpha actinin35.  With this in mind, we designed an experiment that 
incorporated a combined culture atmosphere with the already differentiated 
cardiomyocyte hESCs in direct culture with undifferentiated hADSCs with the hope that 
paracrine signals from the hESCs would be secreted to nearby hADSCs and induce 
cardiac differentiation of the adipose cells.  This experiment incorporated a positive 
control of hESCs (E) cultured alone, a negative control of hADSCs (A) cultured alone, 
and a combined co culture at a 2:1 ratio of hADSCs to hESCs (A+E) to determine if the 
combined culture atmosphere produced more intense cardiac expression than the hESCs 
alone.  The four cardiac proteins tested before were again investigated in this study by 
immunofluorescence imaging found in Figures 3.14-3.17 and by western blot in Figure 
3.18.  
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Figure 3.14: Cells stained for Desmin in green and nuclei in blue (DAPI). A) Coculture group (A+E)  at 10X 
shows no expression of Desmin. B) hESC only positive control group (E) at 10 X magnification showing no 
expression. C) hADSC only group (A) at 10X magnification showing little to no expression. 
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Figure 3.15: Cells stained for MHC in green and nuclei in blue (DAPI). A) Coculture group (A+E)  at 10X shows 
some expression of MHC. B) hESC only positive control group (E) at 20 X magnification showing moderate 
expression. C) hADSC only group at 10X magnification showing significant expression. 
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Figure 3.16: Cells stained for Alpha Actinin in green and nuclei in blue (DAPI). A) Coculture group (A+E)  at 
20X shows good expression of Alpha Actinin. B) hESC only positive control group (E) at 20 X magnification 
showing little expression. C) hADSC only group at 10X magnification showing no expression. 
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Figure 3.17: Cells stained for Troponin T in green and nuclei in blue (DAPI). A) Coculture group (A+E)  at 20X 
shows expression of Troponin T. B) hESC only positive control group (E) at 20 X magnification shows some 
expression. C) hADSC only group at 10X magnification showing little no expression. 
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Figure 3.18: Western Blot data for Myosin Heavy Chain and Alpha Actinin for Cocultured cells.  TOP) 
statistical significance between both A+E, E with negative control group A with n = 2.  BOTTOM) Statistical 
significance between A+E and E showing significantly more Aact in E only groups with p = 0.020 < 0.050. 
Additionally, there is statistical significance between both A+E ,E with negative control A with n = 2. 
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 According to the images, desmin was not present in the cocultured cells or in the 
positive control of hESC cardiomyocytes.  There was little expression of desmin in the 
hADSC only group confirming the results of the previous study (Note: hADSC only 
images are the same images taken from the previous study.  They have been copied for 
comparison purposes).  Western blot data did not show any intensity for the coculture or 
positive control group for desmin further confirming that the tested desmin marker used 
in the assay may not tag for a cardiac specific protein.  Cardiac myosin heavy chain 
images show good expression of the protein in the coculture and positive control groups 
as well as in the negative control group.  Western blot data confirms the presence of the 
protein in the A+E and E groups but not in the A only group.  As with before, this 
anomaly may be attributed to unintentional cardiac differentiation in the tested well of the 
negative control group.  Statistical significance exists between the A+E and E groups 
with the A group for MHC content.  There is no significance between the A+E group and 
E group so no conclusion can be made whether a coculture environment is beneficial for 
producing thick filaments in hADSCs en route to cardiac differentiation.  The presence of 
alpha actinin in both A+E and E groups and not in A show that hESCs definitely contain 
the protein and may be upregulated by hADSCs in coculture with hESCs or the hESCs in 
coculture are the only cells expressing alpha actinin.  By examining the western blot data 
for alpha actinin, it can be seen that there is a statistical significance between A+E and E 
for alpha actinin with higher expression in the E only group.  By this data it can be seen 
that a coculture environment is not beneficial for hADSCs for upregulating alpha actinin.  
Significantly more protein in the positive control group could signify that the coculture 
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environment may actually not be ideal for hADSCs as their interaction with hESCs may 
be toxic for these cells.  Troponin T is present in both A+E and E groups but not in the 
negative control group and confirms its presence in at least the hESC cardiomyocytes.  
No quantifiable data was obtained from the western blot for troponin T so no conclusions 
could be drawn from the interaction of the cells with the expression of troponin T.   
  
 80 
3.5 Three Dimensional Cell Differentiation Study – Cell Spheroids with 5 – AZA 
and Mechanical Stimulation 
 Following the two dimensional studies in which cells were grown as a monolayer, 
we decided to investigate the potential benefits of growing hADSCs into cell spheroids.  
According to a recent study by Zhang, hADSCs grown into three-dimensional spheroids 
expressed upregulated pluripotent markers as compared to a monolayer culture.  
Additionally, they had better proliferative ability and colony forming efficiency.  They 
concluded that spheroid-grown hADSCs had better stemness properties and had increased 
therapeutic potential.  Additionally, they claim that forming cells into aggregates removes 
the need for involvement of any biomaterials, exogenous genes, or proteins and thus 
greatly simplifies the main drawbacks of tissue engineering36.  For this study, we decided 
to apply this concept of spheroid formation along with 5-azacytidine treatment and the 
mechanical stimulating abilities of the Flexcell system to differentiate hADSCs into 
cardiomyocytes.  The following groups were tested: Azt treated cell spheroids (AZT), 
Azt treated spheroids with Flexcell stimulation (M+AZT), Flexcell stimulation only on 
spheroids (M), and a static control spheroid group receiving no stimulation (S).  
Immunofluorescence staining was conducted on the cells while testing the presence of 
alpha actinin, myosin heavy chain, and troponin T.  Desmin was left out of this study as it 
was determined to not be a relevant marker for cardiac differentiation. 
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Figure 3.19: Immunofluorescence imaging of cells stained for Alpha Actinin. A) M+AZT group showing a 
positive stain as well as B) AZT only group, C) M only group, and D) S static group.  All images taken at 10X 
magnification. 
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Figure 3.20: Immunofluorescence imaging of cells stained for Myosin Heavy Chain. A) M+AZT did not express 
MHC and B) AZT only group, C) M mechanical only group, and D) S static group all show a positive stain for 
MHC.  All images taken at 10X magnification. 
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Figure 3.21: Immunofluorescence imaging of cells stained for Troponin T. A) M+AZT group showing a positive 
stain as well as B) AZT only group, C) M only group, and D) S static group.  All images taken at 10X 
magnification. 
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Figure 3.22:  White light images of cell spheroids taken after 7 day incubation in the Flexcell bioreactor. Top) 
Spheroid from group S taken at 10X magnification. Bottom) Spheroid from AZT only group at 10X 
magnification. 
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According to the images, nearly all of the groups displayed all of the cardiac 
markers that were tested.  There did not appear to be a specific group that exhibited 
higher expression than any of the others, as the image capturing technique did not allow 
for contrasting distinctions between groups.  This researcher recommends future 
immunofluorescent imaging to be conducted via a confocal microscope so that individual 
layer of the spheroids can be examined without bleaching of the image.  Unfortunately, 
protein analysis could not be conducted on this data due to time restraints but future 
studies should examine the quantifiable data in order to determine if there is statistical 
significance between groups for the previously tested cardiac markers.  However, in this 
study it is apparent that hADSCs can be successfully formed into spheroids and cultured 
with a large number of cells while differentiating to some degree towards the 
cardiomyocyte phenotype.  Furthermore, these cell constructs successfully adhered to the 
Flexcell plates that feature a soft, silicone elastomer material with similar properties to 
decellularized myocardium scaffolds.  Figure 3.22 illustrates how the cell spheroids 
adhered to the culture plates in which the outer shell of the spheroids branch out and 
anchor the constructs to the substrate.  Future studies should examine the potential of the 
spheroids to adhere and infiltrate into decellularized scaffolds for creating tissue-
engineered constructs. 
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3.6 Three Dimensional Cell Differentiation Study – Cell Spheroids with hADSC and 
hESC Coculture 
 As with the previous study, this final study examined the cardiac differentiating 
potential of hADSCs in a cell spheroid configuration but with the inclusion of a coculture 
environment with hESC cardiomyocytes.  Following the two-dimensional coculture study, 
hADSCs were combined with hESCs at a 2:1 ratio with the same number of cells tested 
as the previous spheroid study.  We wanted to examine the effect of the paracrine 
signaling from the hESCs into hADSCs but while they were in much closer proximity.  
We believed that during the monolayer coculture study, the 2 types of cells in culture 
might not have been in close enough proximity for the paracrine signals of the 
cardiomyocytes to influence the hADSCs or that the cell types could have aggregated 
away from one another.  By forcing the cell types to form into a spheroid configuration 
with one another, the differentiating capacity of the hADSCs should be upregulated.  The 
testing groups followed the same setup as the monolayer coculture study: hADSC and 
hESC co culture group (A+E), hADSC group only (A) as a negative control, and hESC 
group only as a positive control.  Additionally, we wanted to examine if the hADSCs 
expressed the cardiac markers after culturing into spheroids, which would indicate that 
they had differentiated, or if the hESCs were the only cells expressing any cardiac 
markers. Prior to cell culture, hADSCs were all tagged with a fluorescent marker that 
activated at a different wavelength than the cardiac markers.  By overlaying 3 fluorescent 
channels, we could see if the previously tagged hADSCs had indeed differentiated or not. 
Immunofluorescence staining was carried out to test for the presence of the 3 cardiac 
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proteins previously studied excluding Desmin.  Unfortunately, most of the cell spheroids 
did not transfer from the casts they were cultured in or did not adhere to the culture plates 
after transferring and as a result only a few spheroids were available for imaging.  
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Figure 3.23: Immunofluorescence image of cocultured hADSCs with hESCs staining red for Alpha Actinin, 
green for hADSCs, and blue for nuclei. Positive staining for alpha actinin is apparent but not being expressed by 
the hADSCs. 
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Figure 3.24: Immunofluorescence images from each color filter from Figure 3.23. Top) Blue stains for DAPI 
Middle) Green stains for hADSCs, and Bottom) Red stains for alpha actinin 
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 According to this image, the hADSCs labeled green remained intact in the cell 
spheroid along with the hESCs in the coculture environment.  HESCs are represented by 
the DAPI in blue without the green tagging overlay.  In this way, we are able to 
distinguish the two cell types much easier.  It is apparent that the hADSCs are not 
expressing alpha actinin in this case as there are no green/red overlays.  Although the 
cells are in close proximity, the effect of culturing with precomitted cardiomyocytes may 
not have an effect on the hADSC’s capacity to differentiate into cardiomyocytes.  It is 
impossible to make this conclusion without quantifiable data through western blot 
analysis or without more conclusive images but the conclusions from the monolayer 
coculture study suggest that these two cell types may not be compatible and this could be 
the case no matter what conditions the cells are cultured in.  Again, with this type of 
cellular construct, a traditional fluorescent microscope may not be the best imaging tool, 
as it is difficult to see individual cells’ expression as the entire image may become 
bleached with the color of the stain and DAPI.  A confocal microscope would be better 
suited for this type of analysis and is the technique used in other studies that utilize cell 
spheroids.  The loss of cells due to incomplete attachment to the culturing plates hindered 
the experiment but future work with fluorescent tagging on specific cells of a combined 
culture is useful tool.  Before the cells in this study were transferred from their spheroid 
casts, the hESCs began to spontaneously beat within the spheroids.  A short video of this 
phenomenon was recorded using a cell phone camera.  Figure 3.24 shows the individual 
colors from the available immunofluorescence image separately for easier visibility of the 
cells and markers. 
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Chapter 4: Conclusions and Future Directions 
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4.1 Conclusions and Future Directions 
  The initial Flexcell study was ultimately successful in differentiating the tested 
hADSCs to some degree as the cells expressed significant levels myosin heavy chain, an 
important protein in muscle contraction, the anchoring protein alpha actinin, and the 
troponin T subunit that is responsible for regulating muscle contraction.  With all of these 
proteins present in the tested subjects, it is safe to assume that the hADSCs were 
ultimately differentiating towards the cardiomyocyte phenotype.  There was not a specific 
method of stimulation from that Flexcell system that was statistically proven to be better 
than any of the others but all stimulated groups did have significantly higher expression 
than the negative controls indicating that the bioreactor system was responsible to some 
degree to the differentiation of hADSCs to become like cardiomyocytes.  Although the 
cells did not infiltrate deep into the scaffold, they may have began to lie down their own 
matrix in which they began to develop into early cardiac tissue.  
 The two dimension cell culture studies allowed us to examine the effects of a 
chemical treatment as well as a coculture environment on the differentiating capacity of 
hADSCs.  Desmin, the intermediate filament protein present in muscle cells, was found 
to be present in both Azacytidine-treated and negative control groups in the chemical 
treatment study.  Through supporting literature, we concluded that desmin might also be 
expressed in cardiac fibroblasts, indicating that the cells tested in the study might have 
differentiated towards fibroblasts.  Further tests should examine fibroblast markers in 
cardiomyocyte differentiation studies.  Another possible explanation for positive staining 
of cardiac markers in the negative control groups may be attributed to the fact that 
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hADSCs are harvested from human lipo-aspirate and that the cells may have contained 
impurities or other cell types.  This might also explain why myosin heavy chain shows 
abundant expression in the negative control group of hADSCs during the coculture study.  
 Culturing hADSCs in an environment with precomitted cardiomyocytes did not 
yield higher expression for any cardiac specific markers than the positive control group.  
This indicates that paracrine signaling from the hESC derived cardiomyocytes did not 
influence hADSCs to differentiate into cardiomyocytes.  In fact, expression of alpha 
actinin was significantly higher in the positive control group and supports this conclusion. 
 Few conclusions can be drawn from either of the three-dimensional cell culture 
studies, as there was not quantifiable data to examine.  However, we did show that 
hADSCs could easily be formed into cell spheroid aggregates and that spheroids will 
readily adhere to tissue like surfaces.  Additionally they could easily be incorporated into 
the Flexcell system either by directly plating the constructs onto the specialized well 
plates (as we have previously shown) or onto decellularized scaffold while introducing 
physical stimulation.  Indeed, the three-dimensional constructs may not require any 
biomaterial interactions to facilitate cell growth and differentiation; it could be beneficial 
to examine a combined approach with decellularized scaffold.  Although these three-
dimensional constructs may better mimic cell-cell interactions as compared to a 
monolayer culture, several drawbacks do exist that would need to be overcome for this to 
be a viable approach in tissue engineering.  Spheroids lack any kind of vasculature that 
support nutrient delivery, which may not be a problem for small scale aggregates as they 
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can facilitate this via diffusion, but for larger applications with more cells there may be 
unequal nutrient distribution between cells in different layers of the construct37. 
 While most of the work presented here was successful at differentiating hADSCs 
towards cardiomyocytes to some degree, there are still many challenges to overcome 
before a technology such as this can be implemented for the purpose of myocardial 
regeneration.  Introducing a chemical for induced differentiation would need to be tested 
against other tissues of the body to prevent unintended harm to healthy tissue.  One of the 
biggest challenges in developing a tissue-engineered construct on a scaffold still remains 
the method of cell seeding.  Cells need to infiltrate deep into the decellularized scaffolds 
into the intact cell niches at different layers to completely form a functioning tissue or the 
substrate needs to be altered to better accommodate newly differentiated cardiomyocytes.  
The capacity of hADSCs to differentiate into cardiomyocytes is controversial and many 
studies still need to be done to replicate positive results.  Different stem cells types should 
also be considered and tested alongside hADSCs to find the best possible conditions for 
cardiac differentiation. 
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